Bio-Techne executive exercises 794 RSUs
Bio-Techne Corp executive Steven C. Crouse reported routine equity compensation activity involving company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bio-Techne Corp executive Steven C. Crouse reported routine equity compensation activity involving company stock. On May 1, 2026, he exercised 794 Restricted Stock Units, which converted into an equal number of Bio-Techne common shares.
To cover tax obligations, 311 common shares were disposed of through a tax-withholding transaction, a non-market event that does not represent an open-market sale. Following these transactions, Crouse directly holds 6,688 shares of common stock, alongside multiple option and restricted stock unit awards that vest over several future dates.
Insider Trade Summary
794 shares exercised/converted
Exercise
18 txns
Insider
Crouse Steven C.
Role
President - Diag & Spatial Bi
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 794 | $0.00 | $0.00 |
| Exercise | Common Stock | 794 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 311 | $55.02 | $17K |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 14,974 contracts for 14,180 underlying shares (Direct);
Common Stock — 6,337 shares (Direct);
Stock Option (right to buy) — 111,053 contracts (Direct);
Performance Restricted Stock Units — 2,387 contracts (Direct)
Footnotes (16)
- F1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F2. 794 restricted stock units vest on 5/1/2026 and 5/1/2027.
- F3. 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.
- F4. 1,379 restricted stock units vest on 8/15/2026.
- F5. 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.
- F6. 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.
- F7. 100% vested.
- F8. Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
- F9. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.
- F10. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
- F11. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
- F12. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
- F13. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.
- F14. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F15. 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029.
- F16. Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.
Key Figures
RSUs exercised: 794 shares
Shares withheld for taxes: 311 shares
Common shares held after: 6,688 shares
+5 more
8 metrics
RSUs exercised
794 shares
Restricted Stock Units converted to common stock on May 1, 2026
Shares withheld for taxes
311 shares
Tax-withholding disposition (code F) on May 1, 2026
Common shares held after
6,688 shares
Direct ownership following reported transactions
Option strike price
$57.82/share
Stock option on Common Stock expiring March 2, 2036
Option strike price
$53.60/share
Stock option on Common Stock expiring August 15, 2035
Largest option block
24,560 underlying shares
Stock option at $94.52/share expiring August 15, 2029
RSU block
6,529 underlying shares
Restricted Stock Units with exercise price $0.00
Performance RSUs
2,387 underlying shares
Performance Restricted Stock Units on Common Stock
Key Terms
Restricted Stock Units, Performance Restricted Stock Units, Stock Option (right to buy), tax-withholding disposition, +2 more
6 terms
Restricted Stock Units financial
"794 restricted stock units vest on 5/1/2026 and 5/1/2027."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Performance Restricted Stock Units, underlying security title Common Stock"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Option (right to buy) financial
"Stock Option (right to buy), underlying security title Common Stock"
tax-withholding disposition financial
"transaction_action: tax-withholding disposition, code F"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion, code M"
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Bio-Techne (TECH) executive Steven C. Crouse report in this Form 4?
Steven C. Crouse reported equity compensation activity, including the exercise of 794 Restricted Stock Units into Bio-Techne common shares and related tax-withholding. These updates show changes in his holdings, not an open-market stock trade or new cash investment decision.
What does the tax-withholding transaction mean in Steven C. Crouse’s Bio-Techne filing?
The Form 4 shows a code F transaction where 311 shares of Bio-Techne common stock were used to pay tax obligations. This tax-withholding disposition is part of equity compensation processing and does not represent an open-market sale or trading decision.
What derivative or equity awards does Steven C. Crouse retain at Bio-Techne?
The filing lists multiple stock options, Restricted Stock Units, and Performance Restricted Stock Units tied to Bio-Techne common stock, with exercise prices such as $57.82 and $53.60 and various vesting schedules extending to dates like 2036-03-02.
Are the transactions in this Bio-Techne Form 4 open-market buys or sells?
No open-market trades are shown. The key events are a derivative exercise of 794 Restricted Stock Units (code M) and a tax-withholding disposition of 311 shares (code F), both standard mechanisms in equity compensation rather than discretionary market purchases or sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates